FULGENT GENETICS INC
FLGTNASDAQTrading Snapshot
- Day Range
- β
- 52-Week Range
- $13.46 β $31.04
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 27.5M
- Next Earnings
- 2027-02-26
Fundamentals Snapshot
- Annual Revenue
- $323M
- Last Q Revenue
- $90M
- P/E Ratio
- β
- P/S Ratio
- 2.1x
- EPS (TTM)
- $-2.83
- Dividend Yield
- β
- Dilution (1yr)
- +0.4%
FULGENT GENETICS INC
FLGTAbout FULGENT GENETICS INC
Fulgent Genetics, Inc., together with its affiliated companies, offers a comprehensive suite of COVID-19, molecular diagnostic, and genetic testing services to healthcare providers and individuals globally. Their diverse array of genetic tests covers a wide range of applications, including extensive oncology panels and solid tumor molecular profiling for cancer identification, Beacon carrier screening for inherited conditions, and specialized rapid whole genome testing for critically ill infants in NICU and PICU units. Other offerings include a newborn genetic analysis panel, a front-line test to sequence ataxia-related variants, and patient-initiated genetic testing via Picture Genetics. They also provide comprehensive whole exome, clinical exome, whole genome, mutation, and repeat expansion testing, alongside research service tests. For COVID-19, the company delivers next-generation sequencing, reverse transcription polymerase chain reaction (RT-PCR), and antigen-based diagnostic solutions for SARS-CoV-2. Beyond genetic and COVID-19 diagnostics, Fulgent Genetics performs advanced laboratory analyses such as flow cytometry for cell analysis and malignancy monitoring, fluorescence in-situ hybridization (FISH) for specific DNA sequence detection, immunohistochemistry (IHC) to visualize cellular antigens, and cytogenetics for assessing chromosomal anomalies, in addition to molecular testing for both hematopoietic and solid tumors. Their clientele is broad, including insurance companies, hospitals, medical institutions, fellow laboratories, government agencies, payors, municipal bodies, major corporations, and direct patients. The company has formed a strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. Founded in 2011 and headquartered in Temple City, California, the company was previously known as Fulgent Diagnostics, Inc. before adopting its current name in August 2016.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
βLatest News & Updates

Fulgent Genetics (FLGT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Fulgent Genetics (FLGT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could l

Fulgent: 3 Key Takeaways for Long-Term Investors
Billing software fixes are lifting collection rates, but the reimbursement framework behind them remains a variable investors must weigh.

Fulgent Genetics, Inc. (FLGT) Q3 2026 Earnings Call Transcript
Fulgent Genetics, Inc. ( FLGT ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Ming Hsieh - Chairman & CEO Brandon Perthuis - Chief Commercial Officer Paul Kim - Chief Financial Officer Conferenc

What Fulgent Genetics (FLGT) Said on Its Q3 Earnings Call
Fulgent Genetics NASDAQ: FLGT reported third-quarter revenue of $90.4 million, up 8% from a year earlier, as contributions from Bako Diagnostics and StrataDx and improving collections helped lift results. The company rea

Fulgent Genetics, Inc. (FLGT) Reports Q3 Loss, Beats Revenue Estimates
Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to earnings of $0.14 per share a year ago.

Fulgent Reports Third Quarter 2026 Financial Results
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (βFulgent,β or the βCompanyβ), a technology-based company with a well-established laboratory services business and a therapeutic development busine